カテゴリ： GlobalData, アメリカ, 企業調査

Agios Pharmaceuticals Inc (AGIO)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Agios Pharmaceuticals Inc (AGIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7960
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 enzyme used for the treatment of patients with R/R acute myeloid leukemia (AML); and TIBSOVO (ivosidenib), a prescription medicine used to treat adults with AML. Its pipeline products include AG-881, a pan-IDH mutant inhibitor intended for the treatment of hematologic malignancies and solid tumors; AG-270, an inhibitor of methionine adenosyltransferase 2a; and Mitapivat, a potent activator intended for the treatment of patients with pyruvate kinase deficiency. Agios is headquartered in Cambridge, Massachusetts, the US.

Agios Pharmaceuticals Inc (AGIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Agios Pharma Enters into Co-Development Agreement with Celgene 12
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 13
Licensing Agreements 14
CStone Pharma Enters into Licensing Agreement with Agios Pharma 14
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 15
Agios Pharma Exercises Option For Licensing Agreement With Celgene 16
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 18
Equity Offering 19
Agios Pharma Raises USD546 Million in Public Offering of Shares 19
Agios Pharma Completes Underwriter’s Exercise of Over-Allotment of Public Offering of Shares for USD287 Million 21
Agios Pharma Raises USD172.5 Million in Public Offering of Shares 23
Agios Pharma Raises USD253 Million in Public Offering of Shares 25
Agios Pharma Raises USD88 Million in Public Offering Of Shares 27
Agios Pharmaceuticals Prices Offering Of Common Stock 28
Agios Pharma Completes IPO Of Shares For US$122 Million 29
Agios Pharmaceuticals Inc – Key Competitors 30
Agios Pharmaceuticals Inc – Key Employees 31
Agios Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Aug 02, 2018: Agios Reports Second Quarter 2018 Financial Results 33
May 04, 2018: Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day 35
Feb 14, 2018: Agios Reports Fourth Quarter and Full Year 2017 Financial Results 37
Nov 01, 2017: Agios Reports Third Quarter 2017 Financial Results 39
Aug 08, 2017: Agios Reports Second Quarter 2017 Financial Results 41
May 04, 2017: Agios Reports First Quarter 2017 Financial Results 44
Feb 16, 2017: Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones 46
Corporate Communications 48
Sep 04, 2018: Agios Announces Chief Executive Officer Succession Plan 48
Dec 05, 2017: Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors 49
May 31, 2017: Agios Appoints David Scadden, M.D., to the Board of Directors 50
Jan 03, 2017: Agios Appoints Ian Clark to Board of Directors 51
Government and Public Interest 52
Mar 21, 2018: Leukemia Patient’s Legacy Helps Drive Innovative Cancer Clinical Trial 52
Product News 54
12/10/2017: Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency 54
11/01/2017: Agios to Present New Data from PKR Program at the 2017 ASH Annual Meeting 56
07/23/2018: TIBSOVO (ivosidenib), an IDH1 inhibitor approved for treatment of relapsed/refractory acute myeloid leukemia with an IDH1 mutation, available for order at Biologics 57
07/20/2018: Agios’ Tibsovo gains FDA approval as targeted AML treatment 58
Product Approvals 59
Feb 15, 2018: FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation 59
Dec 26, 2017: Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation 60
Clinical Trials 61
Jul 06, 2018: Northwestern University Provides Clinical Update on ivosidenib 61
Jun 18, 2018: Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused 62
Jun 04, 2018: New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients 63
Jun 02, 2018: Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions 65
Jun 02, 2018: Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent 66
Jun 01, 2018: Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors 68
May 16, 2018: Agios to Present Clinical Data on Cancer Drug Candidate AG-881 at ASCO 70
May 16, 2018: Agios to Present Clinical Data on Ivosidenib at ASCO 71
Dec 11, 2017: Data from Phase 1 Studies of Ivosidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation 73
Dec 11, 2017: New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML 75
Nov 17, 2017: Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma 77
Nov 01, 2017: Agios to Present New Data on Ivosidenib at the 2017 ASH Annual Meeting 79
Jun 24, 2017: Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency 80
Jun 03, 2017: Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma 81
May 18, 2017: Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA 83
May 17, 2017: Agios to Present New Data From Ivosidenib Phase 1 Cholangiocarcinoma Study at ASCO 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Agios Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Agios Pharma Enters into Co-Development Agreement with Celgene 12
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 13
CStone Pharma Enters into Licensing Agreement with Agios Pharma 14
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 15
Agios Pharma Exercises Option For Licensing Agreement With Celgene 16
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 18
Agios Pharma Raises USD546 Million in Public Offering of Shares 19
Agios Pharma Completes Underwriter's Exercise of Over-Allotment of Public Offering of Shares for USD287 Million 21
Agios Pharma Raises USD172.5 Million in Public Offering of Shares 23
Agios Pharma Raises USD253 Million in Public Offering of Shares 25
Agios Pharma Raises USD88 Million in Public Offering Of Shares 27
Agios Pharmaceuticals Prices Offering Of Common Stock 28
Agios Pharma Completes IPO Of Shares For US$122 Million 29
Agios Pharmaceuticals Inc, Key Competitors 30
Agios Pharmaceuticals Inc, Key Employees 31

List of Figures
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Agios Pharmaceuticals Inc (AGIO)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • CEMEX, S.A.B. de C.V.：企業の戦略・SWOT・財務情報
    CEMEX, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary CEMEX, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • EnWave Corp (ENW)：企業の財務・戦略的SWOT分析
    EnWave Corp (ENW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Domtar Corporation：企業の戦略・SWOT・財務情報
    Domtar Corporation - Strategy, SWOT and Corporate Finance Report Summary Domtar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Pro-Dex Inc (PDEX)：医療機器：M&Aディール及び事業提携情報
    Summary Pro-Dex Inc (Pro-Dex) is a medical device company that manufactures and markets surgical devices. The company’s products include motion control, finished medical devices, plastic injection molding, micro air-motors, dental products and torque wrenches. Its dental products comprise DLS handpi …
  • Calfrac Well Services Ltd (CFW)：企業の財務・戦略的SWOT分析
    Calfrac Well Services Ltd (CFW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Thetis Pharmaceuticals LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary Thetis Pharmaceuticals LLC (Thetis Pharma) is a drug manufacturing company that offers novel immuno-resolving therapies. The company develops and manufactures drugs for type two diabetes and chronic conditions. Its pipeline products include TP252, TP6211, TP113, and TP 101. Thetis Pharma’s T …
  • Prairie Provident Resources Inc (PPR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Prairie Provident Resources Inc (Prairie Provident) is an exploration and development company that develops oil and natural gas assets. The company offers exploration and development of oil and natural gas with conventional operations primarily focused in the Western Canadian Sedimentary Bas …
  • Haisco Pharmaceutical Group Co Ltd (002653)-製薬・医療分野：企業M&A・提携分析
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations and bulk drugs. The company's product portfolio comprises injection for trace elements, compound vitamin, invert sugar, fat soluble …
  • Larsen & Toubro Ltd (LT)：企業の財務・戦略的SWOT分析
    Larsen & Toubro Ltd (LT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • National Institutes of Health：企業のM&A・事業提携・投資動向
    National Institutes of Health - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's National Institutes of Health Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Kaken Pharmaceutical Co Ltd (4521)：企業の財務・戦略的SWOT分析
    Kaken Pharmaceutical Co Ltd (4521) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Iberia Lineas Aereas de Espana, SA：企業のM&A・事業提携・投資動向
    Iberia Lineas Aereas de Espana, SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Iberia Lineas Aereas de Espana, SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • CK Infrastructure Holdings Ltd (1038)：電力：M&Aディール及び事業提携情報
    Summary CK Infrastructure Holdings Limited (CKI), a subsidiary of CK Hutchison Holdings Limited, is an infrastructure investment company. It holds diversified investment interests across various sectors including energy, rail transportation, water, waste management, and other infrastructure related …
  • InVivoScribe Technologies Inc-医療機器分野：企業M&A・提携分析
    Summary InVivoScribe Technologies Inc (InVivoScribe) is a provider of hematology-oncology testing products and services. The company’s products include lymphotrack and lymphotrack DX assay kits, and custom assay and reagent development products. It also provides general purpose reagents such as PCR …
  • Biocurv Medical Instruments, Inc.：企業の戦略・SWOT・財務分析
    Biocurv Medical Instruments, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biocurv Medical Instruments, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Greatcell Solar Ltd (GSL)-エネルギー分野：企業M&A・提携分析
    Summary Greatcell Solar Ltd (Greatcell Solar), formerly Dyesol Limited, is a renewable energy company that develops and commercializes Perovskite Solar Cells (PSC) or solid-state dye solar cell (DSC), the third generation photovoltaic technology. The company develops a range of PSC chemicals, compon …
  • Toyo Tanso Co Ltd (5310)：企業の財務・戦略的SWOT分析
    Toyo Tanso Co Ltd (5310) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Korean Air Lines Co Ltd：企業の戦略・SWOT・財務情報
    Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Korean Air Lines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Grupo Bimbo S.A. de C.V.：企業の戦略・SWOT・財務情報
    Grupo Bimbo S.A. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Grupo Bimbo S.A. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Kot Addu Power Co Ltd：発電所・企業SWOT分析
    Kot Addu Power Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆